Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30

In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption

(2015) Christel Larbouret et al.   NEOPLASIA

Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy

(2014) Liat Binyamin et al.   JOURNAL OF IMMUNOLOGY

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells

(2013) Josephine L. Klitgaard et al.   BRITISH JOURNAL OF HAEMATOLOGY

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity

(2013) Stefanie Derer et al.   mAbs

Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions

(2013) Christian Kellner et al.   METHODS

Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer

(2013) Maulik Vyas et al.   TRENDS IN MOLECULAR MEDICINE

Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies

(2013) Ursula J. E. Seidel et al.   Frontiers in Immunology

Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype

(2013) Christian Kellner et al.   OncoImmunology

Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications

(2012) Laure Farnault et al.   Clinical & Developmental Immunology

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

(2012) D. O. Persky et al.   HAEMATOLOGICA

Combination strategies to enhance antitumor ADCC

(2012) Holbrook E Kohrt et al.   Immunotherapy

Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

(2012) Nidale Tarek et al.   JOURNAL OF CLINICAL INVESTIGATION

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Cutting Edge: Tumor-Targeting Antibodies Enhance NKG2D-Mediated NK Cell Cytotoxicity by Stabilizing NK Cell-Tumor Cell Interactions

(2012) J. Deguine et al.   JOURNAL OF IMMUNOLOGY

Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity

(2012) C. Kellner et al.   JOURNAL OF IMMUNOLOGY

Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy

(2011) P. Hubert et al.   CANCER RESEARCH

TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy

(2011) H. Lu et al.   CLINICAL CANCER RESEARCH

VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC

(2011) H. Lu et al.   CLINICAL CANCER RESEARCH

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC

(2011) Roland Repp et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity

(2011) C Kellner et al.   LEUKEMIA

Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells

(2011) S Stamova et al.   LEUKEMIA

Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors

(2011) Nicolas F Delahaye et al.   NATURE MEDICINE

Innate or Adaptive Immunity? The Example of Natural Killer Cells

(2011) E. Vivier et al.   SCIENCE

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling

(2010) S. de Haij et al.   CANCER RESEARCH

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors

(2009) Y. T. Bryceson et al.   BLOOD

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

(2009) Cameron S. Brandt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

(2008) M. Peipp et al.   BLOOD

Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress

(2008) Robert K. Oldham et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY